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Drug safety is a major medical concern. Appropri-
ately so. And recent high profile cases have height-
ened the level of concern. These cases include
Vioxx [2], Vytorin and its components [3], Tysabri [4]
and Avandia [5].
These and other cases and the controversies they
have engendered have increased awareness that deal-
ing with and understanding drug safety issues is
enormously difficult. No doubt the final verdict has
been wrong in some cases (not necessarily any of the
ones mentioned above). Drugs are not protected by
the “innocent until proven guilty” principle. Just as
with national security measures, heightened aware-
ness is good, but overreaction can be detrimental to
delivering good medicine.
Inferential problems related to drug safety are nu-
merous as well as difficult. First, there are many
types of serious adverse effects to consider. Drugs
can kill or induce potentially fatal conditions. They
can also lead to one or more effects that detract from
the patient’s quality of life. Multiplicities abound.
Moreover, the same effects usually occur naturally,
perhaps even as part of the disease process for which
the drug is being used. The statistical question is
whether and which serious adverse effects occur at
an increased rate for patients taking the drug.
The medical questions are also difficult. All drugs
cause some side effects, usually in a dose-dependent
fashion. So the issue is the benefit/risk trade-off.
For example, the same serious adverse effect can
have a very different implication in treating cancer,
say, than in the primary prevention of cardiovascu-
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lar events. Indeed, for some cancer therapies, certain
adverse effects are a good thing because they indi-
cate that the therapy is doing a better job of fighting
the tumor: “Congratulations, Ms. Smith, your hot
flashes mean the drug is working!”
Compounding the multiplicity of types of adverse
effects is the multiplicity of drugs, their doses, and
combinations. For any particular adverse effect upon
which no drug has an impact, the data will show that
half of the drugs have some amount of increase in
the incidence of that effect. And some of these in-
creases will be statistically significant. A small pro-
portion of the drugs will be shown to be detrimental
statistically in any particular comparison, but there
are many comparisons. How to separate the signal
from the noise? And how to balance false positives
(rejected drugs that are safe) with false negatives?
Bonferroni and other traditional adjustments for
multiple comparisons are inappropriate when the
measurements concern safety (and they may never
be appropriate!). They are used to protect against
rejecting too many null hypotheses. When the ques-
tion is one of safety, this would mean the more com-
parisons one makes, the more difficult it is to deter-
mine that a drug is unsafe.
Bill DuMouchel has a long history of developing
and using Bayesian hierarchical modeling methods
for addressing multiplicity problems associated with
large, sparse databases. His data mining approaches
as applied to questions of drug safety have been used
by the U.S. Food and Drug Administration, among
others. The methodology he has previously devel-
oped gives a clear view through muddy waters. His
article in this issue makes the view even clearer.
DuMouchel’s application of multivariate Bayesian
logistic regression (MBLR) “borrows strength” in
the usual Bayesian hierarchical modeling sense. For
example, if a drug seems to increase both nausea and
vomiting, then the conclusion about both adverse
effects is stronger than if either were considered by
itself. On the other hand, if the incidence of nausea
1
2 D. BERRY
is elevated but that of vomiting is not, then any
conclusion about nausea based on all the evidence
is less compelling. The borrowing is across clinical
trials as well as across related side effects.
Neither aspect of the borrowing in MBLR is novel
on its own. Bayesian hierarchical modeling is a stan-
dard approach to meta-analysis. And borrowing hi-
erarchically across side effects within body systems
has been proposed previously [1]. But putting the
two together is novel. And it is an important con-
cept. There are usually many clinical trials conducted
of a drug, most with the primary focus on efficacy.
It is important to take advantage of all the evi-
dence. Safety applies to the drug and not to the
trial. A safety signal may be observable only over
several trials. DuMouchel’s methodology is consis-
tent with the synthetic nature of the Bayesian ap-
proach.
This elegant article with its methodology is a wel-
come addition to this important problem area. MBLR
will become a standard method for determining
whether a drug increases the incidence of any ad-
verse drug effects. It will also provide appropriate
estimates for any increases.
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